54711-69-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-TRIFLUOROMETHOXY-PHENYL)-PIPERAZINE is used as a potential therapeutic agent for neurological and psychiatric disorders, leveraging its pharmacological effects to address a range of conditions. Its application in preclinical studies has shown promise, indicating its potential for further development and optimization in drug discovery processes.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, 1-(3-TRIFLUOROMETHOXY-PHENYL)-PIPERAZINE serves as a subject of ongoing research. Its unique chemical structure is being explored for the development of new drugs and the optimization of existing lead compounds, contributing to advancements in the discovery and design of pharmaceuticals.

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 1535-73-5 m-trifluoromethoxyaniline 
• 110-85-0 piperazine 
• 2252-44-0 1-bromo-3-(trifluoromethoxy)benzene 
• 1121600-03-0 C₁₆H₂₁F₃N₂O₃ 
• 179113-90-7 (3-(trifluoromethoxy)phenyl)boronic acid 

Downstream Products

• 1241898-63-4 3-{4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl}-4,5-dihydroisoxazole-5-carboxamide 
• 1241898-67-8 [5-(3-{4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl}isoxazol-5-yl)-1H-tetrazol-1-yl]acetic acid 
• 1241896-94-5 [5-(3-{4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl}isoxazol-5-yl)-2H-tetrazol-2-yl]acetic acid 
• 1241898-66-7 1-[5-(2H-tetrazol-5-yl)isoxazol-3-yl]-4-[3-(trifluoromethoxy)phenyl]piperazine 
• 1241898-65-6 3-{4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl}isoxazole-5-carbonitrile 
• 1241898-64-5 3-{4-[3-(trifluoromethoxy)phenyl]piperazin-1-yl}isoxazole-5-carboxamide 

Relevant academic research and scientific papers

Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents

We developed a focused set of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant and antinociceptive properties. These hybrid compounds demonstrated broad-spectrum protective activity in a range of mouse models, such as the maximal electroshock (MES) test, the pentylenetetrazole-induced seizures (scPTZ), and the 6 Hz (32 mA) seizures. Compound 22 showed the most potent anticonvulsant activity (ED50 MES = 23.7 mg/kg, ED50 6 Hz (32 mA) = 22.4 mg/kg, ED50 scPTZ = 59.4 mg/kg). In addition, 22 revealed potent efficacy in the formalin-induced tonic pain. These in vivo activities of 22 are likely mediated by several targets and may result from the inhibition of central sodium/calcium currents and transient receptor potential vanilloid 1 (TRPV1) receptor antagonism. Finally, the lead compound 22 revealed drug-like absorption, distribution, metabolism, excretion, toxicity (ADME-Tox) properties in the in vitro assays, making it a potential candidate for further development in epilepsy and neuropathic pain indications.

4-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)- N -(4-methoxypyridin-2-yl) piperazine-1-carbothioamide (ML267), a potent inhibitor of bacterial phosphopantetheinyl transferase that attenuates secondary metabolism and thwarts bacterial growth

4′-Phosphopantetheinyl transferases (PPTases) catalyze a post-translational modification essential to bacterial cell viability and virulence. We present the discovery and medicinal chemistry optimization of 2-pyridinyl-N-(4-aryl)piperazine-1-carbothioamides, which exhibit submicromolar inhibition of bacterial Sfp-PPTase with no activity toward the human orthologue. Moreover, compounds within this class possess antibacterial activity in the absence of a rapid cytotoxic response in human cells. An advanced analogue of this series, ML267 (55), was found to attenuate production of an Sfp-PPTase-dependent metabolite when applied to Bacillus subtilis at sublethal doses. Additional testing revealed antibacterial activity against methicillin-resistant Staphylococcus aureus, and chemical genetic studies implicated efflux as a mechanism for resistance in Escherichia coli. Additionally, we highlight the in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetic profiles of compound 55 to further demonstrate the potential utility of this small-molecule inhibitor.

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C═CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1-substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N-CR5R6, C=CR5 or CR13-CR5R6, Y is a bond or -C(O)-, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

Substituted piperazines

Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.